LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Suletud

Sektor Tervishoid

53.29 -0.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

52.82

Max

53.57

Põhinäitajad
By Trading Economics
Sissetulek	14B 1.7B
Müük	300M 12B
P/E Sektori keskmine	14.05 112.16
Aktsiakasum	2.07
Kasumimarginaal	13.77
Töötajad	34,100
EBITDA	13B 4.4B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-4.97 downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024
Järgmine dividendimakse kuupäev	1. nov 2024
Järgmine aktsia dividendi kuupäev (ex-date)	2. jaan 2025

Turustatistika
By TradingEconomics
Turukapital	-1.9B 107B
Eelmine avamishind	53.5
Eelmine sulgemishind	53.29

Uudiste sentiment

By Acuity

34%

66%

100 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

52.41 / 53.4057 Toetus ja vastupanu

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. sept 2024, 13:06 UTC

Suurimad hinnamuutused turgudel

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

26. juuli 2024, 14:08 UTC

Tulu

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26. juuli 2024, 11:54 UTC

Tulu

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25. apr 2024, 14:38 UTC

Tulu

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

7. okt 2024, 14:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 13:45 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 11:54 UTC

Peamised uudised

Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 09:30 UTC

Peamised uudised

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer's Windfall -- Heard on the Street -- WSJ

27. sept 2024, 18:36 UTC

Tulu

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27. sept 2024, 09:15 UTC

Kuumad aktsiad

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

26. sept 2024, 23:20 UTC

Peamised uudised

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- Update

26. sept 2024, 22:56 UTC

Peamised uudised

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ

16. aug 2024, 11:30 UTC

Peamised uudised

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8. aug 2024, 10:30 UTC

Peamised uudised

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26. juuli 2024, 14:51 UTC

Tulu

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26. juuli 2024, 13:53 UTC

Tulu

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26. juuli 2024, 11:28 UTC

Tulu

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26. juuli 2024, 11:14 UTC

Tulu

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26. juuli 2024, 11:06 UTC

Tulu

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26. juuli 2024, 11:06 UTC

Tulu

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26. juuli 2024, 11:04 UTC

Tulu

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26. juuli 2024, 11:04 UTC

Tulu

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q EPS 83c >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19. juuni 2024, 05:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28. mai 2024, 22:51 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25. apr 2024, 12:36 UTC

Tulu

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

-4.97% langus

12 kuu keskmine prognoos

Keskmine 50.72 USD -4.97%

Kõrge 60 USD

Madal 33.1 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

52.41 / 53.4057Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

100 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.